Medicure Inc
Company Profile
Business description
Medicure Inc is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market and sales to the Retail Public of pharmaceutical products. The Company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and increasing its e-commerce and mail order pharmaceutical business. The Company operates under two segments: the marketing and distribution of commercial products and the operation of a retail and mail order pharmacy. It generates the majority of its revenue from the Retail and Mail Order Pharmacy segment.
Contact
1250 Waverley Street
No. 2
WinnipegMBR3T 6C6
CANT: +1 204 487-7412
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
22
Stocks News & Analysis
stocks
ASX healthcare share undervalued post earnings
stocks
ASX energy share sees 363% increase in dividend
stocks
Wide moat share remains cheap despite rising costs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,352.80 | 40.50 | -0.43% |
| CAC 40 | 8,439.20 | 13.81 | -0.16% |
| DAX 40 | 26,266.14 | 159.54 | 0.61% |
| Dow JONES (US) | 53,577.40 | 160.24 | 0.30% |
| FTSE 100 | 10,886.16 | 31.84 | 0.29% |
| HKSE | 25,714.89 | 203.79 | 0.80% |
| NASDAQ | 26,151.30 | 171.11 | 0.66% |
| Nikkei 225 | 66,227.55 | 371.12 | 0.56% |
| NZX 50 Index | 14,034.21 | 41.49 | 0.30% |
| S&P 500 | 7,677.28 | 24.42 | 0.32% |
| S&P/ASX 200 | 9,143.60 | 40.10 | -0.44% |
| SSE Composite Index | 3,918.95 | 29.51 | 0.76% |